NCT00560755View on ClinicalTrials.gov

Safety Study of ProQuad® rHA in Infants (V221-037)

PHASE3CompletedINTERVENTIONAL

Enrollment

3,388

Participants

Timeline

Start Date

October 24, 2007

Primary Completion Date

November 24, 2008

Study Completion Date

November 24, 2008

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

ProQuad®

ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) | Biotech Hunter | Biotech Hunter